Top

Reactions Weekly

Published in:

01-07-2022 | Breast Cancer | Case report

Fulvestrant/palbociclib

Lack of efficacy: case report

Published in: Reactions Weekly | Issue 1/2022

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Matiz GA, et al. CO107 Progression-Free Survival in Patients with Advanced or Metastatic, Hormone Receptor Positive, HER2-Negative Breast Cancer Treated with Palbociclib in Combination with Fulvestrant: A Real-World Study. Value in Health 25 (Spec. issue 7): S324, Jul 2022. Available from: URL: http://doi.org/10.1016/j.jval.2022.04.203 [abstract]

Title: Fulvestrant/palbociclib
Lack of efficacy: case report
Publication date: 01-07-2022
Publisher: Springer International Publishing
Keywords: Breast Cancer
Breast Cancer
Fulvestrant
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-20153-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Fulvestrant/palbociclib

Lack of efficacy: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Antineoplastics

Mesalazine

Doxycycline

Other adverse reaction research

Norepinephrine

Multiple drugs